Series: The T Files — Series 3: “The Injection Dark Ages"
Subtitle: 50 years of yo-yo shots, hormonal roller coasters, and the pharmacology nobody warned you about
Post: 3 of 5
Tags: pharmacokinetics, peak and trough, testosterone injection, serum testosterone, WHO 1990, physiological levels, mood swings, TRT adherence
Word Count: ~1,100
Picture a serum testosterone graph for a man on testosterone enanthate 200mg every two weeks. On day one — injection day — his testosterone is low, probably symptomatic. He receives the injection. By hour 36 to 48, his serum testosterone has climbed to somewhere above 1,200 ng/dL, roughly double the upper bound of normal. Over the next ten days it descends, crossing through physiological range somewhere around days four through twelve. By day fourteen, it’s back near the bottom. He injects again.
Draw this on a graph. What you get is not a flat physiological line. It’s a wave. A pharmacokinetic sine curve. Peak. Trough. Peak. Trough. Every two weeks, forever.
This is the peak-and-trough problem — and for five decades, it was essentially accepted as a feature of TRT rather than a bug.
The Pharmacokinetics, Laid Out Clearly
The basic mechanism is straightforward. Testosterone esters injected into muscle release slowly as the ester is cleaved, producing a delayed but pronounced peak in serum testosterone followed by a gradual exponential decline. The shape of this curve is determined by the half-life of the particular ester.
For testosterone enanthate (TE) and testosterone cypionate (TC) — the two most widely used injectables — the pharmacokinetics play out similarly:
- TE reaches supratherapeutic serum levels at 36–48 hours post-dose. At 200mg every two weeks, the peak exceeds 1,200 ng/dL. Levels return to near the lower therapeutic limit (~300–400 ng/dL) around day 14.
- TC at 200mg reaches a mean peak of approximately 1,112 ng/dL (±297 ng/dL) between days four and five post-injection, declining to approach 400 ng/dL by day 14.
These are published clinical data, not worst-case scenarios. This is what the approved standard-of-care formulations actually did to serum testosterone levels in clinical trials.
For patients on the longer 400mg every-four-weeks regimen, the problem was amplified. The 300mg three-week group dropped below 300 ng/dL by week three. The 400mg four-week group dropped below 300 ng/dL by week four. On the longer intervals, patients were definitionally hypogonadal before their next injection — not borderline, not slightly low, but at concentrations meeting diagnostic criteria for the condition they were being treated for.
What the Body Notices
Human physiology is not indifferent to these fluctuations. Testosterone affects mood, libido, cognitive function, energy, body composition, erythropoiesis, bone metabolism, and a range of other processes. When serum testosterone oscillates between twice-normal and below-normal over a two-to-four-week cycle, the body notices.
In the supratherapeutic phase (first two to three days after injection), patients commonly reported:
- Increased irritability and aggression — what some described as feeling “wired” or short-tempered
- Heightened sexual drive, sometimes uncomfortably so
- Difficulty sleeping
- Skin oiliness and acne flares
- A paradoxical sense of restlessness despite increased energy
In the subtherapeutic phase (the week before the next injection on biweekly dosing, or two weeks on monthly dosing):
- Return of fatigue
- Decreased libido
- Low mood or mild depressive symptoms
- Reduced motivation and cognitive sharpness
- Physical symptoms not unlike mild hypogonadism — because that is, technically, what it was
The formulation’s package insert language describing “fluctuation in mood/libido” as an adverse effect was clinically accurate but underplayed in practice. Physicians often attributed these symptoms to other causes. Patients frequently weren’t told to expect them.
The 1990 Consensus: Someone Finally Said It Out Loud
The pharmacokinetic limitations of injectable testosterone were understood by researchers long before they were acknowledged at the policy level. But in 1990, a WHO/NIH/FDA workshop on male hormonal contraception and TRT produced a formal consensus statement that the major goal of testosterone replacement therapy was to achieve stable physiological serum testosterone levels — and that no currently available preparation was consistently achieving this goal.
This was a significant statement. In 1990, the available preparations were essentially testosterone propionate (every two to three days, declining rapidly), testosterone enanthate (the standard, with its well-documented peaks and troughs), and testosterone cypionate (essentially identical in its problematic kinetics to enanthate). The workshop concluded that all of them fell short of the fundamental therapeutic objective.
The clinical implication was clear: a delivery system that doesn’t maintain physiological levels is failing at its primary job, even if it improves on having no TRT at all. The consensus pointed directly toward what was needed — a formulation capable of maintaining stable serum testosterone throughout a dosing interval.
That formulation didn’t exist yet.
Why the Field Kept Using Injections Anyway
Here’s the uncomfortable part: the 1990 consensus didn’t change prescribing practice overnight. Testosterone enanthate and cypionate remained dominant for well over a decade after that workshop. Why?
Several reasons. First, physician inertia is real. Testosterone enanthate had been prescribed successfully — loosely defined — for forty years. Changing standard of care requires more than a workshop consensus statement; it requires new formulations that actually work better, data supporting those formulations, and a generation of prescribers willing to change their habits.
Second, “better than nothing” is a low but defensible bar. For men with severe primary hypogonadism, imperfect injectable TRT was genuinely life-improving, even with the rollercoaster. The alternative — no treatment — was objectively worse.
Third, shorter injection intervals (weekly or biweekly at lower doses) did substantially reduce the peak-trough amplitude. The Endocrine Society guidelines eventually formalized 75–100mg weekly or 150–200mg every two weeks as preferred alternatives to the big monthly shots. This improvement was meaningful but still didn’t achieve the flat, continuous delivery curve that the 1990 consensus identified as the goal.
The Legacy of Knowing and Waiting
Perhaps the defining characteristic of the injection dark ages is not that the pharmacokinetic problem existed — it’s that the field understood the problem clearly, stated it explicitly, and then waited two more decades for better options.
The transdermal systems that would eventually approach the 1990 consensus goal — patches and gels providing continuous absorption — were in development but not yet practical. And there was another injectable formulation in the pipeline, testosterone undecanoate, which promised the longest duration of action yet. Whether it delivered on that promise — and what rare but serious risks it came with — is the subject of our next post.
Next time: Testosterone undecanoate (Aveed/Nebido) — 750mg every ten weeks, oil-based, castor-carrier. On paper, the ultimate low-frequency injectable. In practice, a formulation with a rare but terrifying adverse effect that required a full FDA Risk Evaluation and Mitigation Strategy program just to keep it on the market.
